The path from medical school in New Delhi to one of the most prestigious academic appointments in American medicine is rarely easy. Ravi Vij has followed that journey while building a career dedicated to understanding and treating blood cancers.
The Indian-born physician-scientist was recently named the Jeffrey S. and Prue H. Gershman Distinguished Professor at Washington University School of Medicine in St. Louis, in recognition of his contributions to cancer research, patient care and medical education. This appointment highlights a career that has helped advance treatment options for multiple myeloma and other blood cancers, while establishing Vig as one of the leading figures in his field.
Ravi Vij’s journey from New Delhi to the forefront of blood cancer treatment
Ravi Vij’s medical journey began at Maulana Azad Medical College in New Delhi, one of the most respected medical institutions in India. After completing his medical education, he moved to the United States to receive advanced training in oncology, hematology, and bone marrow transplantation at the University of Washington School of Medicine.He joined the university’s faculty in 2000 and has steadily built his reputation as a clinician and researcher.
Over the years, he became a key figure in WashU Medicine’s cancer program, helping to cement his position in leukemia research and treatment.Most of Figg’s career has focused on multiple myeloma, a cancer that develops in plasma cells found within the bone marrow. This disease remains one of the most common forms of leukemia and has long presented major challenges to doctors and researchers.Over the past two decades, treatment options for multiple myeloma have improved dramatically.
Advances in immunotherapy, targeted drugs, and stem cell transplantation have increased survival rates and improved quality of life for many patients. Vig has been among the doctors and scientists who have contributed to this progress through clinical care and research.His work has focused on understanding the biological mechanisms of blood cancers and identifying better ways to treat them.
Pioneering research that changed treatment methods
Vig spent years leading clinical trials that explored new treatments for blood cancer.
Many of these studies addressed innovative immunotherapy approaches and stem cell transplantation strategies that later became part of standard treatment practice.At Siteman Cancer Center, where he treats patients and conducts research, Vig has focused on improving understanding of multiple myeloma and related blood disorders. His research has helped advance knowledge about how these diseases develop and respond to treatment.The results of these studies contribute to the growing field of precision medicine, which seeks to tailor treatments to the unique characteristics of individual patients.
More than 200 scientific publications
Throughout his career, Vig has authored more than 200 peer-reviewed scientific papers focusing on multiple myeloma, stem cell transplantation, immunotherapy and related blood disorders.His publications have contributed to a broader understanding of blood cancers and informed treatment decisions in cancer centers around the world.
This work has helped establish him as a respected voice within the international oncology community.
Pioneer in stem cell transplantation
Stem cell transplantation remains one of the most important treatment options for many types of leukemia. The procedure involves replacing damaged bone marrow with healthy blood-forming stem cells, often after intensive chemotherapy.Vij has played an important role in developing transplantation techniques and improving outcomes for patients undergoing these complex treatments.
His contributions helped enhance the reputation of the Washington University School of Medicine as a premier center for stem cell transplantation and cell therapies.University leaders have credited his work with supporting the organization’s growth in areas such as immunotherapy and advanced cancer care.
Educator, teacher, and academic leader
Research accomplishments are only one part of Figg’s professional legacy. He also devoted significant time to mentoring young doctors and scientists.Over the course of his career, he has mentored 25 early-career researchers and clinical trainees, helping to prepare the next generation of oncology and hematology specialists. His commitment to education earned him the Teacher of the Year Award from the Washoe Medicine Hematology Oncology Fellowship Program in 2007.Many of the doctors trained under his supervision have gone on to build successful careers in cancer medicine and research.
Recognized throughout the oncology community
Figg’s expertise has gained him recognition beyond the University of Washington.He has held leadership positions in the American Society of Clinical Oncology and the American Society of Hematology, two organizations that play key roles in shaping the standards of cancer research and treatment.He currently serves as Senior Editor of the journal Clinical Lymphoma, Myeloma and Leukemia, where he helps oversee the publication of new scientific findings and emerging research in this field.These leadership roles reflect the influence he has developed within the broader oncology community.
What does distinguished professorship mean?
The professorships awarded are among the highest honors bestowed by American universities. It is typically reserved for faculty members who have demonstrated exceptional achievement in research, teaching, and public service.The Jeffrey S. and Bro H. Gershman Distinguished Professorship Award was established by a charitable gift from St. Louis.
St. Louis donors Jeffrey and Prue Gershman. By naming Vig as its first bearer, WashU Medicine recognizes his scientific achievements and impact on patient care.The professorship will also help support future research efforts aimed at developing more effective treatments for blood cancer.
A profession dedicated to improving patient outcomes
Ravi Vij’s appointment represents another milestone in a career defined by scientific discovery, clinical excellence and mentorship.
From his beginnings as a medical student in New Delhi to becoming one of America’s leading blood cancer specialists, his work has remained focused on improving outcomes for patients facing life-threatening diseases.As advances in immunotherapy, cellular medicine, and precision oncology continue to reshape cancer care, Vig remains among the researchers helping to drive these changes. His latest honor recognizes his distinguished career and the continuing impact of his work on the future of blood cancer treatment.
